Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis
- 12 October 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (4), 635-643
- https://doi.org/10.1007/s00259-015-3210-7
Abstract
Tumoural portal vein thrombosis (PVT) is a major prognostic factor in hepatocellular carcinoma (HCC). The efficacy of sorafenib, the only treatment approved at an advanced stage, is limited. Based on previous data, selective internal radiation therapy (SIRT), or 90Y radioembolization, seems an interesting option. We aimed to compare both treatments in this population.Keywords
This publication has 30 references indexed in Scilit:
- Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising conceptEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary ResultsInternational Journal of Hepatology, 2013
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal Of Cancer, 2012
- Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary ResultsJournal of Nuclear Medicine, 2012
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survivalHepatology, 2010
- Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosisHepatology, 2007
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trialsHepatology, 1999